Results 21 to 30 of about 316,033 (212)
Management of chronic hepatitis C [PDF]
Postgraduate Medical Journal, 2005 AbstractHepatitis C virus (HCV) infection is transmitted primarily through percutaneous exposure to blood, and most infections are associated with injection drug use. Progression to chronic HCV occurs in 55% to 86% of infected people, and persistent infection is a major cause of cirrhosis, end stage liver disease, and hepatocellular carcinoma.
V, Lo Re, J R, Kostman
openaire +2 more sources
Urinary porphyrin excretion in hepatitis C infection [PDF]
, 1999 A high prevalence of hepatitis C virus infection in porphyria cutanea tarda in some populations suggests a close link between viral hepatitis and alteration of porphyrin metabolism.
Jacob, Karl +2 more
core +1 more source
Bicyclol for chronic hepatitis C
Cochrane Database of Systematic Reviews, 2007 Bicyclol is a novel synthetic 'anti-hepatitis' drug, used in China for chronic hepatitis C. Until now, systematic reviews on bicyclol therapy have not been performed.To study the benefits and harms of bicyclol for patients with chronic hepatitis C.We searched The Cochrane Hepato-Biliary Group Controlled Trials Register (July 2005), the Cochrane Central
Yang, Xiaoyan +3 more
openaire +2 more sources
Journal of the Formosan Medical Association, 2021 Background/Purpose: Effective antiviral-therapy can reduce the risk of liver cirrhosis related hepatocellular carcinoma in patients with chronic hepatitis B and hepatitis C. Yet, the difference of hepatocellular carcinoma development in chronic hepatitis
Ming-Tsung Lin +8 more
doaj +1 more source
Gastroenterology Research and Practice, 2016 Purpose. Helicobacter pylori is a common gastric disease-inducing pathogen. Although an increasing number of recent studies have shown that H. pylori is a risk factor for liver disease, the potential association between H.
Juan Wang +8 more
doaj +1 more source
Level of physicians’ awareness of epidemiology, outcomes, prevention and treatment of chronic hepatitis B and C [PDF]
Клиническая микробиология и антимикробная химиотерапия, 2018 Objective. To evaluate a level of physicians’ awareness of the specific issues of epidemiology, outcomes, prevention and treatment of chronic hepatitis B and C. Materials and Methods.
Baramzina S.V.
doaj +1 more source
Excellent outcome of direct antiviral treatment for chronic hepatitis C in Switzerland
Swiss Medical Weekly, 2018 BACKGROUND The introduction of direct acting antivirals (DAAs) for the therapy of chronic hepatitis C (CHC) has revolutionised treatment and marks a paradigm shift in the approach to this disease, rendering interferon-based therapies obsolete.
Jacqueline A. Bachofner +15 more
doaj +1 more source
Costs of Treatment, Follow-Up, and Complications of Chronic Hepatitis B and Hepatitis C Infections
Balkan Medical Journal, 2013 Background: Few studies have addressed the indirect costs of chronic hepatitis B and C, and none has assessed the real costs of these conditions, including indirect costs caused by loss of work, in Turkey. Aims: This study therefore analysed the costs of
Fatma Banu Karahasanoğlu +3 more
doaj +1 more source
, 2004 We examined correlates of antinuclear antibody (ANA) positivity (ANA+) in individuals with chronic hepatitis C virus (HCV) infection and the effect of positivity on clinical outcome of HCV. Pretreatment sera from 645 patients from three centres in Sweden
Marshall, S +22 more
core +1 more source
Adding low-dose antidepressants to interferon alpha treatment for chronic hepatitis C improved psychiatric tolerability in a patient with schizoaffective psychosis [PDF]
, 2000 Treatment of chronic hepatitis C with interferon alpha (IFN-alpha) is relatively contraindicated in patients with psychiatric disorders because of possible severe psychiatric side effects.
Amann, B. +5 more
core +1 more source